Rosiglitazone
Mostrando 1-12 de 64 artigos, teses e dissertações.
-
1. Molecular mechanism of benign biliary stricture inhibition by rosiglitazone-activated peroxisome proliferator-activated receptor gamma
SUMMARY OBJECTIVE: The aim of this study was to investigate whether rosiglitazone-activated peroxisome proliferator-activated receptor gamma can inhibit the occurrence of benign biliary stricture and further elucidate the relevant molecular signaling mechanism. METHODS: The primary cultured rat biliary fibroblasts following experiments were performed using
Revista da Associação Médica Brasileira. Publicado em: 2022
-
2. Simultaneous determination of anti-diabetic drugs
A novel reverse phase, isocratic HPLC method is described to separate five anti-diabetic drugs i.e., glimepiride, metformin, sitagliptin, rosiglitazone and pioglitazone. Nucleosil C18 analytical column was used as stationary phase, while mobile phase consisted of acetonitrile:phosphate buffer: methanol (40/40/20, v/v) pH 2.0. Effluent was monitored at a flow
Braz. J. Pharm. Sci.. Publicado em: 20/12/2019
-
3. Inhibition of rotavirus ECwt infection in ICR suckling mice by N-acetylcysteine, peroxisome proliferator-activated receptor gamma agonists and cyclooxygenase-2 inhibitors
Live attenuated vaccines have recently been introduced for preventing rotavirus disease in children. However, alternative strategies for prevention and treatment of rotavirus infection are needed mainly in developing countries where low vaccine coverage occurs. In the present work, N-acetylcysteine (NAC), ascorbic acid (AA), some nonsteroidal anti-inflammato
Mem. Inst. Oswaldo Cruz. Publicado em: 2013-09
-
4. Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes m
Braz J Med Biol Res. Publicado em: 25/06/2013
-
5. Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism
The PPARγ nuclear receptor regulates the expression of genes involved in lipid and carbohydrate metabolism, and it has protective effects in some patients with type 2 diabetes. Nevertheless, the therapeutic value of the PPARγ nuclear receptor protein is limited due to the secondary effects of some PPARγ ligands. Because the downstream effects of PPARγ ar
Genet. Mol. Biol.. Publicado em: 18/01/2013
-
6. Métodos de análise da rosiglitazona e pioglitazona e de seus principais metabólitos: aplicações em estudos de metabolismo in vitro / Methods for the analysis of rosiglitazone and pioglitazone and their metabolites: application to in vitro metabolism studies
Estudos de metabolismo in vitro possuem o intuito de caracterizar e quantificar possíveis metabólitos, elucidar as vias metabólicas e sugerir modelos a serem seguidos para a realização de estudos in vivo. Com o intuito de estudar o metabolismo in vitro não estereosseletivo da rosiglitazona (RSG) empregando fração microssomal de fígado de ratos,foi d
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 02/04/2012
-
7. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study
Clinics. Publicado em: 2012
-
8. Effect of silybin on high-fat-induced fatty liver in rats
Silybin, a natural antioxidant, has been traditionally used against a variety of liver ailments. To investigate its effect and the underlying mechanisms of action on non-alcoholic fatty liver in rats, we used 60 4-6-week-old male Sprague-Dawley rats to establish fatty liver models by feeding a high-fat diet for 6 weeks. Hepatic enzyme, serum lipid levels, ox
Brazilian Journal of Medical and Biological Research. Publicado em: 2011-07
-
9. Agonistas PPAR (Rosiglitazona, Bezafibrato e Fenofibrato) e alterações bioquímicas e estruturais em órgãos-alvo de camundongos C57BL/6 alimentados com dieta hiperlipídica rica em sacarose / PPAR agonists (Rosiglitazone, Bezafibrate and Fenofibrate) and biochemical and structural changes in target organs of C57BL/6 mice fed a high-fat high-sucrose diet
This work aimed to evaluate the effect of peroxisome proliferator-activated receptor (PPAR) agonists (rosiglitazone, fenofibrate and bezafibrate) on lipid and glucose metabolism, body mass, and adipose and pancreatic tissue morphology in a model of diet-induced type 2 diabetes and overweight in mice. Two-month-old male C57BL/6 mice were fed a standard chow (
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 07/06/2010
-
10. Regulation of adipogenesis by nucelar receptor PPARγ is modulated by the histone demethylase JMJD2C
A potential strategy to combat obesity and its associated complications involves modifying gene expression in adipose cells to reduce lipid accumulation. The nuclear receptor Peroxisome Proliferator-activated receptor gamma (PPARγ) is the master regulator of adipose cell differentiation and its functional activation is currently used as a therapeutic approa
Genetics and Molecular Biology. Publicado em: 26/11/2010
-
11. CLINICAL, ENDOCRINE AND METABOLIC EFFECTS OF ROSIGLITAZONE ON POLYCYSTIC OVARY SYNDROME / Efeitos clínicos, endócrinos e metabólicos da rosiglitazona na síndrome dos ovários policísticos.
The objectives of the present study are to evaluate the clinical, endocrine and metabolic effects of the rosiglitazone in patients with polycystic ovarian syndrome before and after twelve weeks of treatment. It was be evaluated, besides menstrual pattern and the hyperandrogenism, the hormonal profile (FSH, LH, 17 B-estradiol, total and free testosterone, 17
Publicado em: 2009
-
12. Efeitos metabÃlicos in vivo de derivados Benzilideno-Tiazolidinadionas
Thiazolidinediones are insulin-sensitizing agents that working by binding to PPAR-γ, which leads to alteration in the expression of key regulators of lipid homeostasis, glucoregulatory and insulin resistance gene. In this study, it was evaluated the effect of treatment with novel benzylidene thiazolidinediones (BTZDs) derivatives: 5-(4-chlorobenzylidene
Publicado em: 2009